ClinicalTrials.gov
ClinicalTrials.gov Menu

A Short Term Open, Randomized Cross-over Trial Exploring the Effect of Carbonic Anhydrase Inhibition by Acetazolamide on Sleep Apnea Associated Hypertension and Vascular Dysfunction

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02220803
Recruitment Status : Completed
First Posted : August 20, 2014
Last Update Posted : August 16, 2016
Sponsor:
Information provided by (Responsible Party):
Jan Hedner, Göteborg University

Brief Summary:

This is a short term open, randomized cross over trial to explore and compare the efficacy of pharmacological carbonic anhydrase (CA) inhibition on obstructive sleep apnea (OSA) related hypertension. Patients will be randomized to receive Acetazolamide(Diamox®)(ACZ), Continuous Positive Airway Pressure (CPAP)or CPAP plus ACZ for 2 weeks. Following a 2 week wash-out period all study participants will receive the alternative treatment regimen. The total length of the study will be 10 weeks. The effects of carbonic anhydrase inhibition on blood pressure,hemodynamics and sleep apnea will be investigated.

Study hypothesis:

Carbonic anhydrase inhibition alone or in combination with nCPAP will prominently reduce blood pressure in patients with OSA. Further it is hypothesized that CA inhibition will induce a direct pharmacological effects on vascular stiffness as evidenced in overnight non-invasive assessments of vascular stiffness and that this effect will be particularly strong in patients also responding with a reduction of blood pressure.


Condition or disease Intervention/treatment Phase
Obstructive Sleep Apnea Sleep-Disordered Breathing Blood Pressure Hypertension Drug: Acetazolamide Device: nasal Continuous Positive Airway Pressure (nCPAP) Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 13 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Short Term Open, Randomized Cross Over Trial Trial Exploring the Effect of Carbonic Anhydrase Inhibition by Acetazolamide on Sleep Apnea Associated Hypertension
Study Start Date : March 2014
Actual Primary Completion Date : August 2016
Actual Study Completion Date : August 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sleep Apnea

Arm Intervention/treatment
Active Comparator: Acetazolamide and CPAP

Acetazolamide: Diamox®. Hard white capsule, 250 mg. The total treatment is 4 weeks (2+2 weeks). Dosing of acetazolamide will be up-titrated during 3 days according to manufacturer instruction and titration scheme of the study. Maximum dosage (750mg) following titration will be administered as morning (250 mg) and evening(500mg) dosages.Evening medication should be taken 2 hours before bedtime.

CPAP: Continuous positive nasal airway pressure (nCPAP) delivers slightly pressurized air throughout the breathing cycle and will be given through a mask that is placed and secured over the person's nose. nCPAP titration will follow clinical routines. The standard setting is a pressure delivery in the pressure range 5-15 mbar. The adequate performance of the device is controlled by user time readers and built-in memory cards and control readings are routinely performed at the end of each treatment regimen. Total duration of CPAP treatment is 4(2+2) weeks.

Drug: Acetazolamide
Acetazolamide, 250mg tablets, will be administrated as multiple doses. Dosing of acetazolamide will be up-titrated during 3 days according to manufacturer instruction and titration scheme of the study. Maximum daily dosage is 750 mg (equivalent of 3 tablets/daily). Evening medication should be taken 2 hours before bedtime. The total length of Acetazolamide treatment will be 4 weeks (2x2) including 3 days of titration phase of the drug.
Other Names:
  • Diamox®
  • ATC-code: S01E C01

Device: nasal Continuous Positive Airway Pressure (nCPAP)
Other Names:
  • nCPAP - Nasal Continuous Positive Airway Pressure.
  • ResMed - S9 AutoSet™

Active Comparator: CPAP
Continuous positive nasal airway pressure (nCPAP) delivers slightly pressurized air throughout the breathing cycle and will be given through a mask that is placed and secured over the person's nose. nCPAP titration will follow clinical routines whereby the patient is equipped with an autotitrating device (Sullivan S9). The standard setting is a pressure delivery in the pressure range 5-15 mbar and the full treatment is maintained in the patient´s home. The adequate performance of the device is controlled by user time readers and built-in memory cards and control readings are routinely performed at the end of each treatment regimen. Patients will be encouraged via telephone calls for maximum use. Total duration of CPAP treatment is 4(2+2) weeks.
Device: nasal Continuous Positive Airway Pressure (nCPAP)
Other Names:
  • nCPAP - Nasal Continuous Positive Airway Pressure.
  • ResMed - S9 AutoSet™

Experimental: Acetazolamide
Acetazolamide (Diamox®) 250 mg. Hard white capsule. The total length of acetazolamide treatment will be 4 weeks (2x2) including 3 days of titration phase of the drug. Dosing of acetazolamide will be up-titrated during 3 days according to manufacturer instruction and titration scheme of the study. Maximum dosage (750mg) following titration will be administered as morning (250 mg) and evening(500mg)dosages.Evening medication should be taken 2 hours before bedtime. The tablets will be swallowed with 300 ml of water (room temperature) in an upright body position and preferably in connection to a meal.
Drug: Acetazolamide
Acetazolamide, 250mg tablets, will be administrated as multiple doses. Dosing of acetazolamide will be up-titrated during 3 days according to manufacturer instruction and titration scheme of the study. Maximum daily dosage is 750 mg (equivalent of 3 tablets/daily). Evening medication should be taken 2 hours before bedtime. The total length of Acetazolamide treatment will be 4 weeks (2x2) including 3 days of titration phase of the drug.
Other Names:
  • Diamox®
  • ATC-code: S01E C01




Primary Outcome Measures :
  1. The primary efficacy variable is the reduction in systolic/diastolic office blood pressure (mmHg) between the treatment regimens [ Time Frame: Baseline to 10 weeks ]
    The effect will be expressed in terms systolic and diastolic blood pressure (resting office, provoked office and 24 hour).


Secondary Outcome Measures :
  1. The secondary objective is to investigate the direct effect of CA inhibition on sleep disordered breathing (Apnea-hypopnea Index, AHI score (events/hour) in the subgroup of patients with OSA after treatment [ Time Frame: Baseline to 10 weeks ]
    Secondary objectives include Apnea-hypopnea Index, AHI score in patients with OSA after treatment.


Other Outcome Measures:
  1. Other outcome measures include the assessment of vascular function. [ Time Frame: Baseline to 10 weeks ]

    Vascular function will be assessed by:

    Cold pressor test: assessing vascular response and pulse excitability. Arteriograph: Standard radial pulse assessment to determine pulse wave and augmentation.

    Aritmethic stress test: Evaluate cardiovascular responses such as heart rate, blood pressure and heart rate variability induced by mental work.

    CardioPAT: Finger plethysmograph measuring peripheral arterial tone as well as endothelial function following brachial artery compression (ischemia).

    Full overnight two channel MC Cardio recorder (Sleep apnea indices and recording of continuous oximetry signal for vascular stiffness, microcirculation and chemosensory vascular responsiveness)

    Markers of OSA include:


  2. Markers of OSA such as oxygen desaturation, mean overnight oxygenation, and sleep quality (by polygraphic (PG) assessment, daytime sleepiness, patient-reported outcomes as well as effects on metabolic markers. [ Time Frame: Baseline to 10 weeks ]

    Markers of OSA include: Oxygen desaturation (ODI, events/hour), Mean overnight oxygenation (Spo2, %), Daytime sleepiness: Epworth Sleepiness Scale (ESS), Functional Outcomes of Sleep Questionnaire (FOSQ).

    Patient reported outcomes include: Clinical Global rating Impression and Severity (CGI/S), Columbia suicidal severity rating scale (CSSR-S) Metabolic markers include:Total Cholesterol, HDL, LDL, Triglycerides, Insulin, HbA1C, Fasting plasma glucose and cathecholamines.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Provision of informed consent prior to any study specific procedures
  • Males 18 to 75 years
  • An Apnea-Hypopnea Index (AHI)>15 and an Epworth Sleepiness Scale score (ESS)>6 as verified by a PSG recording.
  • Patients with established hypertension (systolic/diastolic blood pressure >= 160/95, either systolic or diastolic accounted for).
  • Clinically normal physical findings and laboratory values, as judged by the investigator
  • Body mass index >= 35 kg/m2

Exclusion Criteria:

  • Hypersensitivity to sulfonamides or acetazolamide-
  • Patients with ongoing medication with other sulphonamides or patients any specific antihypertensive treatment.
  • History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity.
  • Subjects with a seizure disorder
  • Patients with clinically verified central sleep apnea
  • Clinically significant renal (serum creatinine >2.0 mg/dL or >130 micromol/L), neurological, metabolic (e.g. Type 1 or 2 diabetes), haematological or hepatic disease (ASAT or ALAT >2 times the upper limit of normal).
  • Subjects with an occupational risk potentially exaggerated by daytime sleepiness such as handling complex machinery or professional driving
  • Unstable angina pectoris, unstable hypertension (or poorly controlled diabetes (HbA1C < 52 mmoles/mol, or fasting plasma glucose >7 mmoles/l).
  • Clinically significant congestive heart failure.
  • Myocardial infarction or coronary vessel intervention within the previous 6 months period.
  • Subjects with uncontrolled hypertension (defined as a diastolic blood pressure ≥110 mmHg and/or a systolic blood pressure ≥180 mmHg with or without medication).
  • Previously diagnosed or treated clinically significant cardiac arrhythmia
  • Clinically significant chronic pulmonary or gastrointestinal disease.
  • Clinical history of depression as judged by the investigator or other previous or present clinically significant psychiatric disease
  • Suspected or confirmed poor compliance
  • Alcohol or drug abuse during the last year.
  • Subjects with any other significant condition that, in the opinion of the investigator, could interfere with participation in the study.
  • Severe nocturnal hypoxia defined as more than 10 episodes with an oxygen desaturation exceeding 50% or signs of lacking resaturation between desaturations on previous recordings according to investigators judgment
  • Participation in another clinical study during the last 6 months.
  • Inability to understand and complete the questionnaires.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02220803


Locations
Sweden
Center for Sleep and Vigilance disorders
Gothenburg, Vastra Gotaland, Sweden, 40530
Sponsors and Collaborators
Göteborg University
Investigators
Principal Investigator: Jan Hedner, MD. Prof. Dept of internal medicine. Center for Sleep and Vigilance disorders.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Jan Hedner, Professor. MD, Göteborg University
ClinicalTrials.gov Identifier: NCT02220803     History of Changes
Other Study ID Numbers: CA-BP13
2013-004866-33 ( EudraCT Number )
First Posted: August 20, 2014    Key Record Dates
Last Update Posted: August 16, 2016
Last Verified: August 2016

Keywords provided by Jan Hedner, Göteborg University:
Acetazolamide
Zonegran
Obstructive Sleep apnea
Apnea
Respiration Disorders
Sleep Disorders
Cardiovascular
Hypertension
Carbonic Anhydrase
Carbonic Anhydrase Inhibitors
Enzyme Inhibitors
Sulfonamides
Therapeutic Uses
Pharmacologic Actions
Vascular stifness

Additional relevant MeSH terms:
Hypertension
Apnea
Sleep Apnea Syndromes
Sleep Apnea, Obstructive
Vascular Diseases
Cardiovascular Diseases
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
Signs and Symptoms
Sleep Disorders, Intrinsic
Dyssomnias
Sleep Wake Disorders
Nervous System Diseases
Acetazolamide
Anticonvulsants
Carbonic Anhydrase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Diuretics
Natriuretic Agents
Physiological Effects of Drugs